WS Value & Dossier GmbH
Your specialists for market access and reimbursement
Value & Dossier GmbH advises pharmaceutical companies and biotechnology companies throughout the AMNOG process and on all matters relating to market access and reimbursement. Based on our long-standing expertise, we advise you on the development of the best strategy, the preparation of your benefit dossier for the G-BA assessment and the price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Your success is what drives us. We will make sure that your new product will be reimbursed in the best possible way.
Our Services
Strategic Market Access Consulting
German Benefit Assessment (AMNOG)
AMNOG price negotiations 
Reference pricing for pharmaceuticals
European Health Technology Assessment (EU-HTA)
European Reference Price Calculator
Reimbursement of Medical Devices
HTA Services“We offer individual and company-specific solutions focussing on the value of the product while implementing it accordingly in the required benefit dossiers.”
Your team of specialists from Value & Dossier
f. l. t. r.: Vanessa Henkel (M. Sc.), Dr. Angela Lammert, Dr. Sandra Kiehlmeier, Dr. Caroline Steinmetz, Dr. Jasmin Gömann, Hanna Klimek (M. Sc.), Christian Schneider, Dr. Willi Schnorpfeil
Recent Articles
EU-HTA: Open call for Joint Scientific Consultations
EUnetHTA21 offers early dialogue Joint Scientific Consultations (JSC) in parallel to the EMA scientific advice for medicinal products
Challenges and Chances of the EU-HTA
The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of
EU-HTA: Regulation 2021/2282 is effective starting today
The Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health
